lenalidomide,Bortezomib,Dexamethasone
Takeda
thierry fancon concluded that the difference of pfs of determination study = 82 mos vs ifm2009 = 52 mos in srmm is most likely due to longer revlimid maintenance 3yrs in determination trial #ims2022 
Director of the Multiple Myeloma and Amyloidosis Service @columbiacancer - Associate Editor @JCO_ASCO - Tweets are my own